Christopher Eccleston Talks THOR And HEROES REBORN Return Possibilities
Christopher Eccleston's filmography is filled with a pretty impressive amount sci-fi and superhero assignments. There's Doctor Who, Heroes, Thor: The Dark World, G.I Joe: The Rise of Cobra and a host of other projects. Recently, MTV caught with Eccleston and asked him about possibily returning to the role of Malekith the Accurrsed for another Marvel Studios adventure and/or returning to the role of Claude Rains on NBC's upcoming, Heroes Reborn. Said The Ninth Doctor on returning to Heroes, "Of course, yeah, I had a great time on the show! Yeah. I’d always be interested. That was a great character. I love that guy." However, Eccleston was not as enthusiastic about the possibility of suiting up one more time as the dark elf, Malektih. "Eh, the makeup was a little, I don’t think I’d like to revisit six hours of makeup every day. And I think Malekith has served his time. The way of the Marvel films, the Thor films, they have a new villain every time." Yet Eccleston does leave the door open, just a tiny bit. "I do think there was more to be said and done with [Malekith]."
Most famously known as The Ninth Doctor on Doctor Who, actor Christopher Eccleston also starred in Marvel Studios' Thor: The Dark World and had a brief stint on NBC's superhero drama, Heroes.
If we're being frank, Malekith was a pretty weak villain, one of the least developed within all of the Marvel films. I actually found Adewale Akinnuoye-Agbaje's Algrim/Kurse to be much more interesting as an on-screen foil for Chris Hemsworth and Tom Hiddleston. Still, given the display of powers by Malekith during the film's climax, it's probably not entirely out of the realm of possibility that someone like Thanos could rebuild/resuscitate Malekith. On the Hereoes Reborn front, Eccleston's character was one of the highlights of the show during a time when the show was at its best. He'd be welcome return to the franchise.
: ComicBookMovie.com is protected under the DMCA (Digital Millenium Copyright Act) and... [MORE]